Nuveen LLC Takes Position in Applied Therapeutics Inc. $APLT

Nuveen LLC purchased a new position in Applied Therapeutics Inc. (NASDAQ:APLT) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 281,028 shares of the company’s stock, valued at approximately $137,000. Nuveen LLC owned approximately 0.20% of Applied Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Nuveen Asset Management LLC grew its holdings in Applied Therapeutics by 7.5% in the fourth quarter. Nuveen Asset Management LLC now owns 281,028 shares of the company’s stock worth $241,000 after purchasing an additional 19,608 shares during the period. Deutsche Bank AG grew its holdings in shares of Applied Therapeutics by 0.7% during the fourth quarter. Deutsche Bank AG now owns 4,468,122 shares of the company’s stock valued at $3,843,000 after buying an additional 30,520 shares during the last quarter. Ground Swell Capital LLC bought a new position in Applied Therapeutics during the fourth quarter valued at approximately $27,000. Toronto Dominion Bank bought a new position in Applied Therapeutics during the fourth quarter valued at approximately $27,000. Finally, Wellington Management Group LLP lifted its position in Applied Therapeutics by 17.8% during the fourth quarter. Wellington Management Group LLP now owns 237,850 shares of the company’s stock valued at $204,000 after purchasing an additional 35,884 shares during the period. 98.31% of the stock is owned by institutional investors.

Applied Therapeutics Stock Up 1.9%

Shares of NASDAQ:APLT opened at $0.47 on Friday. Applied Therapeutics Inc. has a 52 week low of $0.30 and a 52 week high of $10.62. The stock has a market capitalization of $68.25 million, a P/E ratio of -1.05 and a beta of 2.06. The firm has a fifty day simple moving average of $0.45 and a two-hundred day simple moving average of $0.44.

Applied Therapeutics (NASDAQ:APLT) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02. On average, analysts expect that Applied Therapeutics Inc. will post -0.65 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Applied Therapeutics to a “sell” rating in a research report on Saturday, July 26th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $1.50 price target on shares of Applied Therapeutics in a research report on Wednesday, May 14th. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.